The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NANORAY-312: A phase III pivotal study of NBTXR3 activated by investigator’s choice of radiotherapy alone or radiotherapy in combination with cetuximab for platinum-based chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma.
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD
 
Caroline Hoffmann
Honoraria - Nanobiotix
 
Zoltan Takacsi-Nagy
Honoraria - Nanobiotix
 
Xavier Liem
No Relationships to Disclose
 
Sébastien Salas
Honoraria - Nanobiotix
 
Anais Debard
Employment - Nanobiotix
 
Laetitia Finzi
Employment - Nanobiotix
 
Leonard A Farber
Employment - Nanobiotix
 
Miranda Gogishvili
No Relationships to Disclose
 
Giorgi Kristesashvili
Employment - Nanobiotix
 
Tamta Makharadze
Honoraria - Nanobiotix
 
Sue S. Yom
Research Funding - BioMimetix (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Springer; UpToDate